Biosynex SA (ENXTPA:ALBIO) agreed to acquire Bigix Pharma Srl on September 22, 2022. BIGIX PHARMA distributes different product ranges in the medical equipment segment and achieved in 2021 a turnover of approximately 2.9 million. The finalization of this acquisition will take place in the coming days, after completion of the formalities required in Italy.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.09 EUR | -0.73% | -19.80% | -51.02% |
2023 | Biosynex: merger with Theradiag completed | CF |
2023 | Biosynex SA Reports Earnings Results for the Half Year Ended June 30, 2023 | CI |
1st Jan change | Capi. | |
---|---|---|
-51.02% | 46.99M | |
+0.89% | 12.8B | |
-10.29% | 7.61B | |
+1.78% | 5.41B | |
-1.16% | 4.51B | |
+5.74% | 4.49B | |
-50.70% | 3.29B | |
+12.21% | 2.73B | |
-16.13% | 2.02B | |
-11.50% | 1.73B |
- Stock Market
- Equities
- ALBIO Stock
- News Biosynex
- Biosynex SA agreed to acquire Bigix Pharma Srl.